| 001 | 169020 | ||
| 005 | 20240229133635.0 | ||
| 024 | 7 | _ | |a 10.3324/haematol.2021.278894 |2 doi |
| 024 | 7 | _ | |a pmid:34047179 |2 pmid |
| 024 | 7 | _ | |a 0390-6078 |2 ISSN |
| 024 | 7 | _ | |a 1592-8721 |2 ISSN |
| 024 | 7 | _ | |a altmetric:106659644 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-01188 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Teich, Katrin |b 0 |
| 245 | _ | _ | |a Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. |
| 260 | _ | _ | |a Pavia |c 2021 |b Ferrata Storti Found |
| 264 | _ | 1 | |3 online |2 Crossref |b Ferrata Storti Foundation (Haematologica) |c 2021-05-27 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1642078639_473 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Nov 1;106(11):2986-2989 |
| 520 | _ | _ | |a Not available. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 542 | _ | _ | |i 2021-05-27 |2 Crossref |u https://creativecommons.org/licenses/by-nc/4.0/legalcode |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 700 | 1 | _ | |a Krzykalla, Julia |0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |b 1 |u dkfz |
| 700 | 1 | _ | |a Kapp-Schwoerer, Silke |b 2 |
| 700 | 1 | _ | |a Gaidzik, Verena I |b 3 |
| 700 | 1 | _ | |a Schlenk, Richard F |b 4 |
| 700 | 1 | _ | |a Paschka, Peter |b 5 |
| 700 | 1 | _ | |a Weber, Daniela |b 6 |
| 700 | 1 | _ | |a Fiedler, Walter |b 7 |
| 700 | 1 | _ | |a Kühn, Michael W M |b 8 |
| 700 | 1 | _ | |a Schroeder, Thomas |b 9 |
| 700 | 1 | _ | |a Mayer, Karin |b 10 |
| 700 | 1 | _ | |a Lübbert, Michael |b 11 |
| 700 | 1 | _ | |a Ramachandran, Dhanya |b 12 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 13 |u dkfz |
| 700 | 1 | _ | |a Ganser, Arnold |b 14 |
| 700 | 1 | _ | |a Döhner, Hartmut |b 15 |
| 700 | 1 | _ | |a Heuser, Michael |b 16 |
| 700 | 1 | _ | |a Döhner, Konstanze |b 17 |
| 700 | 1 | _ | |a Thol, Felicitas |b 18 |
| 773 | 1 | 8 | |a 10.3324/haematol.2021.278894 |b Ferrata Storti Foundation (Haematologica) |d 2021-05-27 |n 11 |p 2986-2989 |3 journal-article |2 Crossref |t Haematologica |v 106 |y 2021 |x 1592-8721 |
| 773 | _ | _ | |a 10.3324/haematol.2021.278894 |0 PERI:(DE-600)2805244-4 |n 11 |p 2986-2989 |t Haematologica |v 106 |y 2021 |x 1592-8721 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:169020 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2020-06-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-06-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-06-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-06-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-06-12 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |f 2020-06-12 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |f 2020-06-12 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-06-12 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.3324/haematol.2018.188888 |9 -- missing cx lookup -- |2 Crossref |u Lambert J, Pautas C, Terré C. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019; 104(1):113-119. |
| 999 | C | 5 | |a 10.1158/1078-0432.CCR-11-0486 |9 -- missing cx lookup -- |2 Crossref |u Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17(20):6417-6427. |
| 999 | C | 5 | |a 10.1200/JCO.2016.71.2513 |9 -- missing cx lookup -- |2 Crossref |u Lamba JK, Chauhan L, Shin M. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2017; 35(23):2674-2682. |
| 999 | C | 5 | |a 10.1517/14712598.2014.922534 |9 -- missing cx lookup -- |2 Crossref |u Thol F, Schlenk RF. Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert Opin Biol Ther. 2014; 14(8):1185-1195. |
| 999 | C | 5 | |a 10.1517/14712598.1.5.893 |9 -- missing cx lookup -- |2 Crossref |u Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001; 1(5):893-901. |
| 999 | C | 5 | |a 10.1038/leu.2017.187 |9 -- missing cx lookup -- |2 Crossref |u Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017; 31(9):1855-1868. |
| 999 | C | 5 | |a 10.1016/S1470-2045(14)70281-5 |9 -- missing cx lookup -- |2 Crossref |u Hills RK, Castaigne S, Appelbaum FR. The addition of gemtuzumab ozogamicin to induction chemotherapy in acute myeloid leukaemia: an individual patient data meta-analysis of randomised trials in adults. Lancet Oncol. 2014; 15(9):986-996. |
| 999 | C | 5 | |a 10.1007/s12185-012-1123-9 |9 -- missing cx lookup -- |2 Crossref |u Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol. 2012; 96(2):153-163. |
| 999 | C | 5 | |a 10.1200/JCO.19.01406 |9 -- missing cx lookup -- |2 Crossref |u Schlenk RF, Paschka P, Krzykalla J. Gemtuzumab ozogamicin in NPM1 -mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study. J Clin Oncol. 2020; 38(6):623-632. |
| 999 | C | 5 | |a 10.1038/nature05887 |9 -- missing cx lookup -- |2 Crossref |u Easton EF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-1093. |
| 999 | C | 5 | |a 10.1200/JCO.2011.35.4894 |9 -- missing cx lookup -- |2 Crossref |u Thol F, Damm F, Lüdeking A. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-2896. |
| 999 | C | 5 | |a 10.1182/blood-2016-08-733196 |9 -- missing cx lookup -- |2 Crossref |u Döhner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447. |
| 999 | C | 5 | |a 10.1182/blood-2009-07-235358 |9 -- missing cx lookup -- |2 Crossref |u Döhner H, Estey EH, Amadori S. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3):453-474. |
| 999 | C | 5 | |a 10.1182/blood-2017-08-802157 |9 -- missing cx lookup -- |2 Crossref |u Gale RE, Popa T, Wright M. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood. 2018; 131(4):468-471. |
| 999 | C | 5 | |a 10.1002/ajh.25854 |9 -- missing cx lookup -- |2 Crossref |u Short NJ, Richard-Carpentier G, Kanagal-Shamanna R. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020; 95(9):E225-E228. |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::